## MAY - 4 2001

K003123 Page 162

# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA and 21 CFR 807.92

1. Submitter's Name: SUNDER BIOMEDICAL TECH. CO., LTD

Address:

10F-1, 1-67, Wu-Chun Rd. Taichung, Taiwan

Phone:

886-4-23755650

Fax:

886-4-23755651

Contact:

Tony Hung

2. Device name: RENAX A.V. FISTULA NEEDLE SET

SUNDER A.V. FISTULA NEEDLE SET

Common Name: A.V. FISTULA NEEDLE SET

Classification Name: NEEDLE, FISTULA

3. Classification: Class II

Panel: 78

Product Code: FIE

4. Predicate Device: BIOTEQUE A.V. FISTULA NEEDLE SET

5. Device Description: SUNDER A.V.FISTULA NEEDLE SET consist of the

following 6 major components: the stainless needle, protector cap for needle, the plastic butterfly wing, the PVC tubing, the

female luer, the cap for female luer. These 6 major

components assembled together as A.V. Fistula Needle Set for use during hemodialysis procedures. Various models of needle size manufactured such as 15 gauge, 16 gauge, 17

gauge.

**INDICATIONS FOR USE:** 6. Intended Use:

> The RENAX A.V. FISTULA NEEDLE SET is used during hemodialysis. It is a part of accessory of extra corporeal system for treatment of renal failure. A. V. Fistula Needle applied on the access site of patient's vessel to obtain blood flow adequate to pass through the dialysis, and the reinfusion of dialysed blood back to patient via the fistula needle during hemodialysis.

### USERS TO INSTALL THE DEVICE:

Trained nurses or the doctors.

ENVIRONMENT FOR THE DEVICE TO BE USED:

The hemodialysis center.

#### **SPECIAL NOTES:**

The Arterial-Venous Fistula (A.V.F.) Needle Set must be installed by trained nurses and doctors. The patients can not influence the use of the device.

7. Performance

Summary:

In terms of Physical specification, Chemical specification, Biological specification and Sterilization specification, the device conforms to applicable standards included ISO 10993 series, ISO 11607-1, ISO 11135, USP pyrogenic standards and related standards...etc.

### 8. Conclusions:

The SUNDER A.V. FISTULA NEEDLE SET has the same intended use and similar technological characteristics as the BIOTEQUE A.V. FISTULA NEEDLE SET (k993118). Moreover, bench testing contained in this submission demonstrate that any differences in their technological characteristics do not raise any new questions of safety or effectiveness. Thus, The SUNDER A.V. FISTULA NEEDLE SET is substantially equivalent to the predicate devices.

K003123 Page 20f2



MAY - 4 2001

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Tony Hung President Sunder Biomedical Tech. Co., Ltd. 10F-1, 1-67, Wu-Chuan Rd. TAICHUNG CITY TAIWAN Re: K003123

Renax® A.V. Fistula Needle Sets Dated: February 1, 2001 Received: February 7, 2001

Regulatory Class: II

21 CFR §876.5540/Procode: 78 FIE

Dear Mr. Hung:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours

Daniel G. Schultz, M.D.

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

510(k) NUMBER (IF KNOWN): <u>KOO3123</u>
DEVICE NAME: <u>RENAX A.V. FISTULA NEEDLE SET</u>
INDICATIONS FOR USE:

The RENAX A.V. FISTULA NEEDLE SET is used during hemodialysis. It is a part of accessory of extra corporeal system for treatment of renal failure. A. V. Fistula Needle applied on the access site of patient's vessel to obtain blood flow adequate to pass through the dialysis, and the reinfusion of dialysed blood back to patient via the fistula needle during hemodialysis.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEED.)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use V
(Per 21 CFR 801.109)

or

Over –The-Counter-Use \_\_\_\_\_ (Optional Format 1-2-96)

(Division Sign-Off)

Division of Reproductive, Abdominal, ENT,

and Radiological Devices

510(k) Number 5003/23